IIM
ABOS icon

INTECH Investment Management’s Acumen Pharmaceuticals ABOS Stock Holding History

INTECH Investment Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,540
Closed -$31.4K – 2448
2025
Q1 		$31.4K Buy
28,540
+9,693
+51% +$13.8K ﹤0.01% 2478
2024
Q4 		$32.4K Buy
+18,847
New +$45.4K ﹤0.01% 2361

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

INTECH Investment Management's ABOS Position: Q2 2025 in Review

INTECH Investment Management sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 28,540 shares — an estimated $31.4K sold.

INTECH Investment Management first reported a position in ABOS in Q4 2024 and held it in 2 quarters. The position peaked at $32.4K in Q4 2024. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

  • INTECH Investment Management reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • INTECH Investment Management sold 28,540 Acumen Pharmaceuticals shares in Q2 2025, an estimated $31.4K.
  • INTECH Investment Management first reported a position in Acumen Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • INTECH Investment Management's Acumen Pharmaceuticals position peaked at $32.4K in Q4 2024.
  • 71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on INTECH Investment Management's 13F filing for Q2 2025, filed 8 Aug 2025.